Cognitive Hyper-performance – Effects of Stimulating Substances in chess-players

Cognitive Hyper-performance – Effects of Stimulating Substances in chess-players - CHESS

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

DRKS

Registry ID

DRKS00003112

Enrollment

Registered

2011-05-26

Start date

2011-05-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Group 1: Caffeine (Coffeinum) 2x 200 mg in tablets (2. application 4 hours after first application) Group 2: Methylphenidat (Ritalin) 2x 20 mg in tablets (2. application 4 hours after first applicati

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inculsion criteria: - male - healthy - 18. – 60. years old - existing ELO-Number/ DWZ (Deutsche Wertungszahl)

Exclusion criteria

Exclusion criteria: Exclusion criteria: - existing somatic disease (e.g. Diabetes mellitus, known Liver- and kidney disease with necessity of use of prescription drugs - existing psychiatric disease (actual, past) (e.g. organic psychiatric diseases, Alzheimer´s disease, bipolar disorders, addiction, schizophrenia) with the necessity of use of prescription drugs - addiction of psychoactive substances actual and in the past - smoker and quitter ( 5 cups per day - people with unregular day- and night-sleep (e.g. shift worker)

Design outcomes

Primary

Measure	Time frame
Primary outcome is the results of chess games measured by the number of games (win, lose, tie) under the influence of caffeine, methylphenidate, modafinil and placebo for elucidating cognitive effects of the used substances.	—

Secondary

Measure	Time frame
Secondary outcome for the cognitive effectiveness of methylphenidate, modafinil and caffeine is: - time until decision of chess game(s) - outcome of neurcognitive standardized tests (Tower of Hanoi, Trail-Making-Test, Stroop-Test, Psycho-Motor-Vigilanz-Test, Wisconsin-Card-Sorting-Test, Balloon Analog Risk Task) - measuring of risk taking behaviour motivation, mood and subjective substance effects using standardized questionnaires (Evaluation of Risk Task EVAR, Profile of Mood Status POMS, Achievement Motive Scale AMS, Drug Effects Questionnaire DEQ) - adverse events AEs are monitored during day of trial and one day later	—

Measure

Time frame

Secondary outcome for the cognitive effectiveness of methylphenidate, modafinil and caffeine is: - time until decision of chess game(s) - outcome of neurcognitive standardized tests (Tower of Hanoi, Trail-Making-Test, Stroop-Test, Psycho-Motor-Vigilanz-Test, Wisconsin-Card-Sorting-Test, Balloon Analog Risk Task) - measuring of risk taking behaviour motivation, mood and subjective substance effects using standardized questionnaires (Evaluation of Risk Task EVAR, Profile of Mood Status POMS, Achievement Motive Scale AMS, Drug Effects Questionnaire DEQ) - adverse events AEs are monitored during day of trial and one day later

—

Countries

Germany

Contacts

Public ContactHarald Ballo

Internistische Praxis und Präsident des Hessischen Schachverbande

harald.ballo@t-online.de069-81-2626

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026